AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial
logo

CDTX(Delisted)

Cidara Therapeutics·NASDAQ
--
--(--)
6.47 / 10
Outperform

Capital flow assessment yields 7.49/10, denoting robust fund flow characteristics. Strengths in overall, block, Small, and Extra-large trends confront pressures from Medium and Large patterns, resulting in positive liquidity outlook. Analyst sentiment reflects cautiously optimistic analyst perspective with balanced view. The rating profile includes Strong Buy(20.0%), Buy(20.0%), Neutral(60.0%) from 5 analytical reports, supported by 5.46 historical weighted rating.

FundamentalSentiment(6.47)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

20%

Buy

20%

Hold

0%

Sell

0%

Strong Sell

0%

Date2025-11-07
InstitutionRBC Capital
Times predicted2
Historical Win Rate100.0%